These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 11464912)

  • 1. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
    Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
    Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of prognostic factors in the Austrian A-NB87 Neuroblastoma Study].
    Ladenstein R; Ambros PF; Urban C; Ambros IM; Fink FM; Zoubek A; Grienberger H; Schmitt K; Kerbl R; Horcher E; Amann G; Höfler G; Heinzl H; Gadner H; Mutz I
    Klin Padiatr; 1996; 208(4):210-20. PubMed ID: 8926686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
    Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
    J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
    J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYCN protein expression as a predictor of neuroblastoma prognosis.
    Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
    Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.
    Spitz R; Hero B; Simon T; Berthold F
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3368-73. PubMed ID: 16740759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.
    Caron H; van Sluis P; de Kraker J; Bökkerink J; Egeler M; Laureys G; Slater R; Westerveld A; Voûte PA; Versteeg R
    N Engl J Med; 1996 Jan; 334(4):225-30. PubMed ID: 8531999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.
    Brinkschmidt C; Christiansen H; Terpe HJ; Simon R; Lampert F; Boecker W; Dockhorn-Dworniczak B
    Med Pediatr Oncol; 2001 Jan; 36(1):11-3. PubMed ID: 11464859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localised and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique.
    Rubie H; Plantaz D; Coze C; Michon J; Frappaz D; Baranzelli MC; Chastagner P; Peyroulet MC; Hartmann O;
    Med Pediatr Oncol; 2001 Jan; 36(1):247-50. PubMed ID: 11464897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
    Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
    Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
    Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
    Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable outcome of triploid neuroblastomas: a contribution to the special oncogenesis of neuroblastoma.
    Spitz R; Betts DR; Simon T; Boensch M; Oestreich J; Niggli FK; Ernestus K; Berthold F; Hero B
    Cancer Genet Cytogenet; 2006 May; 167(1):51-6. PubMed ID: 16682287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French society of pediatric oncology.
    Minard V; Hartmann O; Peyroulet MC; Michon J; Coze C; Defachelle AS; Lejars O; Perel Y; Bergeron C; Boutard P; Leverger G; Stephan JL; Thyss A; Chastagner P; Couillault G; Devalck C; Lutz P; Mechinaud F; Millot F; Plantaz D; Rialland X; Rubie H
    Br J Cancer; 2000 Oct; 83(8):973-9. PubMed ID: 10993641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience.
    Canete A; Gerrard M; Rubie H; Castel V; Di Cataldo A; Munzer C; Ladenstein R; Brichard B; Bermúdez JD; Couturier J; de Bernardi B; Pearson AJ; Michon J
    J Clin Oncol; 2009 Mar; 27(7):1014-9. PubMed ID: 19171715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
    Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
    Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification.
    Laprie A; Michon J; Hartmann O; Munzer C; Leclair MD; Coze C; Valteau-Couanet D; Plantaz D; Carrie C; Habrand JL; Bergeron C; Chastagner P; Défachelles AS; Delattre O; Combaret V; Bénard J; Pérel Y; Gandemer V; Rubie H;
    Cancer; 2004 Sep; 101(5):1081-9. PubMed ID: 15329919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.
    London WB; Castleberry RP; Matthay KK; Look AT; Seeger RC; Shimada H; Thorner P; Brodeur G; Maris JM; Reynolds CP; Cohn SL
    J Clin Oncol; 2005 Sep; 23(27):6459-65. PubMed ID: 16116153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between the number of segmental chromosome aberrations and the age at diagnosis of diploid neuroblastomas without MYCN amplification.
    Souzaki R; Tajiri T; Teshiba R; Kinoshita Y; Yosue R; Kohashi K; Oda Y; Taguchi T
    J Pediatr Surg; 2011 Dec; 46(12):2228-32. PubMed ID: 22152855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
    Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
    J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overall genomic pattern is a predictor of outcome in neuroblastoma.
    Janoueix-Lerosey I; Schleiermacher G; Michels E; Mosseri V; Ribeiro A; Lequin D; Vermeulen J; Couturier J; Peuchmaur M; Valent A; Plantaz D; Rubie H; Valteau-Couanet D; Thomas C; Combaret V; Rousseau R; Eggert A; Michon J; Speleman F; Delattre O
    J Clin Oncol; 2009 Mar; 27(7):1026-33. PubMed ID: 19171713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.